The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...
ATLANTA, GA - June 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases ...
Ten of 13 patients with leukemic pulmonary infiltrates (LPI) and chronic lymphocytic leukemia (CLL) had single or multiple nodular/mass-like opacities, authors found. The study authors explained that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback